Evogene

EVGN

Biotechnology · Healthcare

Price

$0.63

+0.04 (+7.56%)

Market Cap

$5.4M

Exchange

NASDAQ Global Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count falling — buybacks

−80.8% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 41.0M (2021) → 7.9M (2025)

Evogene is an Israeli biotechnology company that uses computational biology and artificial intelligence to develop new products for agriculture, medicine, and industrial uses. Its core platform, called GeneRator, helps design microbes, genes, and small molecules faster than traditional lab methods. The company works across several subsidiaries focused on areas like crop protection, crop seeds, human health drugs, and cannabis.

Evogene makes money mainly through research collaborations, licensing deals, and grants — not yet from large-scale product sales. It is headquartered in Rehovot, Israel, and operates as a small-cap company with a market cap near zero, meaning it is still in early-stage development. The company has been spending far more than it earns, as shown by its deeply negative operating margin, which is a significant risk. Its main growth driver is whether its AI-based platform can produce commercially successful products across its subsidiaries before it runs out of funding.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-86.3% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-57.9% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$8M/ year

↓ Declining (-36% vs prior year)

207.5% of revenue

11.5x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

1.0%ownership

Relatively low insider ownership

Cash Runway

~13 months

$13M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Adequate runway but may need to raise capital within 2 years

Revenue declining

Evogene's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

61.1%

Premium pricing power — 61.1% gross margin

Operating Margin

-943.1%

Losing money on operations — -943.1%

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-71.2%

Shrinking sales (-71.2% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-637.4%

Burning cash (-637.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial